OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan.
+ 1 more risk
Flawless balance sheet and overvalued.
Share Price & News
How has OncoTherapy Science's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 30O's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 30O underperformed the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: 30O underperformed the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is OncoTherapy Science's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is OncoTherapy Science undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 30O's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 30O's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 30O is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 30O is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 30O's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 30O is good value based on its PB Ratio (3.1x) compared to the DE Biotechs industry average (3.5x).
How is OncoTherapy Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OncoTherapy Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine OncoTherapy Science's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- OncoTherapy Science competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has OncoTherapy Science performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 30O is currently unprofitable.
Growing Profit Margin: 30O is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 30O is unprofitable, and losses have increased over the past 5 years at a rate of -8% per year.
Accelerating Growth: Unable to compare 30O's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 30O is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 30O has a negative Return on Equity (-63.51%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is OncoTherapy Science's financial position?
Financial Position Analysis
Short Term Liabilities: 30O's short term assets (¥4.6B) exceed its short term liabilities (¥267.0M).
Long Term Liabilities: 30O's short term assets (¥4.6B) exceed its long term liabilities (¥132.0M).
Debt to Equity History and Analysis
Debt Level: 30O is debt free.
Reducing Debt: 30O has not had any debt for past 5 years.
Inventory Level: 30O has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 30O's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 30O has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 30O has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of -7.1% each year.
What is OncoTherapy Science's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 30O's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 30O's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 30O's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 30O's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 30O's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jae-Hyun Park 0
Jae-Hyun Park serves as Director at OncoTherapy Science, Inc. since June 2018 and also it's President and Chief Executive Officer since 2019.
|President||1.1yrs||no data||no data|
|Full-Time Auditor||11.7yrs||no data||3.32% ¥4.2m|
|External Director||5.4yrs||no data||no data|
|External Auditor||15.7yrs||no data||0.018% ¥22.4k|
|External Director||9.7yrs||no data||0.014% ¥18.1k|
|External Auditor||5.4yrs||no data||no data|
|External Director||5.4yrs||no data||no data|
|Director||0yrs||no data||no data|
Experienced Board: 30O's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.5%.
OncoTherapy Science, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: OncoTherapy Science, Inc.
- Ticker: 30O
- Exchange: DB
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥15.165b
- Listing Market Cap: JP¥127.403m
- Shares outstanding: 176.33m
- Website: https://www.oncotherapy.co.jp
Number of Employees
- OncoTherapy Science, Inc.
- Building D
- 11th Floor, Kanagawa Science Park
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4564||TSE (The Tokyo Stock Exchange)||Yes||Common Stock||JP||JPY||Dec 2003|
|30O||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2003|
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company’s clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for soft tissue synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer’s disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/16 22:18|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.